Evidence map›Paper›PMID 36737754›Full record

ArticleBMC biology2023

Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains.

Rebecca Sternke-Hoffmann, Thomas Pauly, Rasmus K Norrild, Jan Hansen, Florian Tucholski, Magnus Haraldson Høie, Paolo Marcatili, Mathieu Dupré, Magalie Duchateau, Martial Rey and 10 more

Open access · goldAbstract read
In one paragraph

Article in BMC biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Autophagy-related mechanisms for treatment of multiple myeloma.Cancer drug resistance (Alhambra, Calif.) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 4 countries.

Rebecca Sternke-HoffmannInstitut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
Thomas PaulyInstitut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
Rasmus K NorrildDepartment of Biotechnology and Biomedicine, Technical University of Denmark, Lyngby, Denmark.
Jan HansenCondensed Matter Physics Laboratory, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
Florian TucholskiInstitut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
Magnus Haraldson HøieDepartment of Health Technology, Technical University of Denmark, Lyngby, Denmark.
Paolo MarcatiliDepartment of Health Technology, Technical University of Denmark, Lyngby, Denmark.
Mathieu DupréMass Spectrometry for Biology Unit, CNRS USR2000, Institut Pasteur, 75015, Paris, France.
Magalie DuchateauMass Spectrometry for Biology Unit, CNRS USR2000, Institut Pasteur, 75015, Paris, France.
Martial ReyMass Spectrometry for Biology Unit, CNRS USR2000, Institut Pasteur, 75015, Paris, France.
Christian MalosseMass Spectrometry for Biology Unit, CNRS USR2000, Institut Pasteur, 75015, Paris, France.
Sabine MetzgerCologne Biocenter, Cluster of Excellence on Plant Sciences, Mass Spectrometry Platform, University of Cologne, Cologne, Germany.
Amelie BoquoiDepartment of Hematology, Oncology and Clinical Oncology, Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany.
Florian PlattenCondensed Matter Physics Laboratory, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
Stefan U EgelhaafCondensed Matter Physics Laboratory, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
Julia Chamot-RookeMass Spectrometry for Biology Unit, CNRS USR2000, Institut Pasteur, 75015, Paris, France.
Roland FenkDepartment of Hematology, Oncology and Clinical Oncology, Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany.
Luitgard Nagel-StegerInstitut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany.
Rainer HaasDepartment of Hematology, Oncology and Clinical Oncology, Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany. Haas@med.uni-duesseldorf.de.
Alexander K BuellInstitut für Physikalische Biologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany. alebu@dtu.dk.ORCID 0000-0003-1161-3622
Heinrich Heine University Düsseldorf · DECentre National de la Recherche Scientifique · FRForschungszentrum Jülich · DETechnical University of Denmark · DKPaul Scherrer Institute · CHUniversity of Cologne · DE

Funding

EPIC-XS 823839Novo Nordisk Fonden NNFSA170028392
6 · The paper itself

Abstract

backgroundIn a range of human disorders such as multiple myeloma (MM), immunoglobulin light chains (IgLCs) can be produced at very high concentrations. This can lead to pathological aggregation and deposition of IgLCs in different tissues, which in turn leads to severe and potentially fatal organ damage. However, IgLCs can also be highly soluble and non-toxic. It is generally thought that the cause for this differential solubility behaviour is solely found within the IgLC amino acid sequences, and a variety of individual sequence-related biophysical properties (e.g. thermal stability, dimerisation) have been proposed in different studies as major determinants of the aggregation in vivo. Here, we investigate biophysical properties underlying IgLC amyloidogenicity.

resultsWe introduce a novel and systematic workflow, Thermodynamic and Aggregation Fingerprinting (ThAgg-Fip), for detailed biophysical characterisation, and apply it to nine different MM patient-derived IgLCs. Our set of pathogenic IgLCs spans the entire range of values in those parameters previously proposed to define in vivo amyloidogenicity; however, none actually forms amyloid in patients. Even more surprisingly, we were able to show that all our IgLCs are able to form amyloid fibrils readily in vitro under the influence of proteolytic cleavage by co-purified cathepsins.

conclusionsWe show that (I) in vivo aggregation behaviour is unlikely to be mechanistically linked to any single biophysical or biochemical parameter and (II) amyloidogenic potential is widespread in IgLC sequences and is not confined to those sequences that form amyloid fibrils in patients. Our findings suggest that protein sequence, environmental conditions and presence and action of proteases all determine the ability of light chains to form amyloid fibrils in patients.

Indexed as

Immunoglobulin Light ChainsMultiple MyelomaAmino Acid SequenceAmyloidHumansProteolysisAmyloidImmunoglobulin Light ChainsAL amyloidosisAmyloidImmunoglobulinLight chainMultiparametric approachMultiple myeloma

Identifiers

PMID36737754
PMCPMC9898917
OpenAlexW4319079246

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.